| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Sales | $3K-97.6% | $134K-79.2% | $645K-30.9% | $934K |
| Cost of goods sold | $3K-99.5% | $627K-17.1% | $757K-1.3% | $767K |
| Gross profit (loss) | $268+100.1% | -$493K-342.0% | -$112K-166.9% | $167K |
| General and administrative expenses $0 and $33,071in stock-based compensation, respectively | $16.0M-1.9% | $16.3M-12.5% | $18.6M+16.4% | $16.0M |
| Research and development $10,000 and $6,712,663 in stock-based compensation, respectively | $3.2M-70.7% | $10.9M+53.9% | $7.1M-2.7% | $7.3M |
| Sales and marketing $473,311 and $0 in stock-based compensation, respectively | $402K+103.2% | $198K-26.5% | $269K-85.4% | $1.8M |
| Total operating expenses | $19.6M-28.5% | $27.4M+5.5% | $26.0M+1.2% | $25.6M |
| NET LOSS FROM OPERATIONS | -$19.6M+29.8% | -$27.9M-6.9% | -$26.1M-2.3% | -$25.5M |
| Interest expense | -$681K+83.7% | -$4.2M+0.2% | -$4.2M-457.1% | -$753K |
| Interest income | $200K+13667.5% | $1K-85.7% | $10K-82.3% | $57K |
| Amortization of debt discount | -$1.7M+46.2% | -$3.2M-44.7% | -$2.2M-43.2% | -$1.5M |
| Gain (loss) on note exchange agreement | -$209K | — | $52K | — |
| Change in fair value of derivative liability | $15K-96.5% | $415K | — | — |
| Change in fair value of Evofem warrants | $2.8M | — | — | — |
| Impairment of Evofem F-1 Preferred Stock | -$23.8M | — | — | — |
| Bargain purchase gain from purchase of Evofem convertible notes | $328K | — | — | — |
| Impairment of fixed assets | -$412K | — | — | — |
| Total other expense | -$23.2M-224.4% | -$7.2M-13.1% | -$6.3M-191.6% | -$2.2M |
| Net loss before income taxes | -$42.8M-22.2% | -$35.0M-8.1% | -$32.4M-17.1% | -$27.6M |
| NET LOSS | -$42.8M-22.2% | -$35.0M-8.1% | -$32.4M-17.1% | -$27.6M |
| Deemed Dividends | -$1.4M+76.5% | -$5.9M-1746.7% | -$320K | — |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | -$1.1M-87.0% | -$574K-5869.7% | -$10K | — |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | -$43.1M-6.8% | -$40.4M-23.4% | -$32.7M-18.3% | -$27.6M |
| Net loss per share, basic (in Dollars per share) | -$1153.83+100.0% | -$22147415.22-81811.4% | -$27038.26-4428.1% | -$597.12 |
| Net loss per share, diluted (in Dollars per share) | -$1153.83+100.0% | -$22147415.22-81811.4% | -$27038.26 | — |
| Weighted average number of shares outstanding during the period, basic (in Shares) | 37K+1867650.0% | 2-99.8% | 1K-97.4% | 46K |
| Weighted average number of shares outstanding during the period, diluted (in Shares) | 37K+1867650.0% | 2-99.8% | 1K | — |
| Net Loss | -$42.8M-22.2% | -$35.0M-8.1% | -$32.4M-17.1% | -$27.6M |
| Change in valuation of Evofem note | $1.3M | — | — | — |
| TOTAL COMPREHENSIVE LOSS | -$41.5M-18.6% | -$35.0M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.